Texas is currently home to 4880 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Recruiting
To learn if the combination of pirtobrutinib (also called LOXO-305), venetoclax, and obinutuzumab is safe and effective when given to patients with chronic lymphocytic leukemia (CLL) or Richter transformation (RT) who have not previously received treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Recruiting
Despite recent advances in the treatment of solid tumors in general, advanced (metastatic) disease remains mostly incurable and there is an urgent need to develop new therapeutic options for these patients, particularly investigational drugs with novel mechanisms of action. The investigation of new combination regimens of non-crossresistant agents with acceptable-and not completely overlapping-toxicities has been a major way to improve response rate and outcome of patients with advanced solid tu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
Recruiting
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: UT Southwestern, Dallas, Texas
Conditions: Spontaneous Coronary Artery Dissection
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Recruiting
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
12/12/2024
Locations: Family Psychiatry of The Woodlands, The Woodlands, Texas
Conditions: Schizophrenia
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Recruiting
Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently taking, as part of your medical care, at least one of the drugs we are studying. We are interested in studying drugs commonly prescribed to women who are breastfeeding so we can learn more about the amount of drug that is transferred to breastmilk and estimate how much of drug that is consumed by bre... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/12/2024
Locations: Texas Tech University Health Sciences Center School of Medicine., Amarillo, Texas
Conditions: Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Modifying the Inpatient Environment to Reduce Delirium in Older Adults
Recruiting
The overall goal is to reduce the incidence and burden of delirium, as measured by the delirium burden index (DBI) among hospitalized older adults (≥70 years), by modifying the inpatient environment to decrease its sleep antagonism. The investigators propose to implement a multi-modal sleep hygiene (MMSH) bundle, an enhancement of a previously reported sleep-focused intervention which had 88 - 100% compliance for intervention components, and reduced ICU delirium by 50%.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
12/11/2024
Locations: Houston Methodist Baytown Hospital, Baytown, Texas
Conditions: Delirium, Sleep Hygiene
RESTORE: An RCT to Evaluate the Efficacy of the Revi System
Recruiting
The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/11/2024
Locations: Urology Partners of North Texas, Arlington, Texas
Conditions: Urinary Urge Incontinence
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
Recruiting
The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency (AATD) via nebulization. This study is designed to evaluate safety and pharmacodynamics of KB408 in adults with AATD with a PI\*ZZ or PI\*ZNull genotype. Three planned dose levels of KB408 will be evaluated in single dose escalation cohorts. Subjects tak... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/11/2024
Locations: Renovatio Clinical, The Woodlands, Texas
Conditions: Alpha 1-Antitrypsin Deficiency
A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
Recruiting
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas
Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Dell Children's Medical Center, Austin, Texas
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rat... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/11/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Recruiting
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks. Participa... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: U.T. MD Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer